Revolutionizing Patient-Centric Supply Chains To Improve Vaccine Access

By Dan Bell, Senior VP Innovation & Strategic Operations, and Vesna Stamenkovic, Director, Global Vaccine Lead at Marken

Global disruptions over the past several years have had an undeniable impact on the vaccine landscape, including research trends, risk assessment strategies, and supply chain obstacles. Although vaccines are one of the fastest growing markets in the pharmaceutical industry, they have always come with manufacturing and distribution challenges, and stakeholders must now adapt to accommodate a rapidly growing market with an increasingly patient-centric focus.

Transparent collaboration and innovation are essential to establishing an infrastructure that supports more agile business models and empowers widespread vaccine access, including for low- or middle-income countries (LMICs).